MoonLake Immunotherapeutics Secures $75M to Propel Next‑Generation Nanobody® Therapies for Immunologic Diseases

MoonLake Immunotherapeutics AG is thrilled to announce a major milestone with a successful funding round that raised USD 75,000,000 to accelerate its mission of transforming the treatment landscape for immunologic diseases. As a clinical-stage biopharmaceutical company, MoonLake is at the forefront of developing breakthrough therapies using its revolutionary Nanobody® technology. This cutting-edge platform is not only innovative but also uniquely positioned to address some of the most challenging inflammatory conditions affecting patients, including inflammatory skin and joint diseases. The new capital injection will enable MoonLake to expand its research and development efforts, hastening its promising clinical programs from early-stage discovery to advanced trials. The additional funds will support an expansion of the scientific team and foster collaborations with academic institutions and industry partners, ensuring that the company remains agile and responsive to evolving patient needs. Furthermore, the investment will assist in the scaling of manufacturing capabilities, meeting stringent quality standards while streamlining production processes to ensure a timely and effective rollout of next-level medicines. This funding announcement marks a significant step forward in MoonLake’s vision to redefine therapeutic innovation and deliver substantial benefits for patients suffering from immunologic disorders. With an unwavering commitment to scientific excellence and patient care, the company is poised to make major contributions in the field of immunotherapy and set new industry benchmarks. MoonLake Immunotherapeutics continues to drive forward with the passion and determination necessary to translate advanced science into tangible health outcomes, ultimately reshaping the way inflammatory diseases are managed and treated on a global scale.